Biomolecules

The Heart-Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications

By Aodi Fan, Xinwei Chen, Ke Yang, Lan Li

Abstract

The heart-kidney axis has emerged as a central framework for understanding the bidirectional interactions that drive cardiorenal syndrome and broader cardiovascular-kidney-metabolic (CKM) disease.

The paper

Aodi Fan, Xinwei Chen, Ke Yang, Lan Li

Tianjin University of Traditional Chinese Medicine

Biomolecules, 27 Aug 2026, CC BY

doi.org/10.3390/biom16091241 PubMed 42793073

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Journal of Clinical Medicine4 Oct 2026
Early physical therapy links to lower mortality in heart failure
Clinical Journal of the American Society of Nephrology4 Oct 2026
Lower physical performance links to heart failure and death in CKD

The Heart-Kidney Axis in Heart Failure and Chronic Kidney Disease: Mechanisms, Mediators, and Therapeutic Implications

Abstract

The paper

More on Heart failure

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

Drug class linked to fewer deaths or complications in kidney disease

Early physical therapy links to lower mortality in heart failure

Lower physical performance links to heart failure and death in CKD